Manager TitleAgeSince
Chief Executive Officer 43 28/10/2025
Chief Tech/Sci/R&D Officer 67 -
Chief Operating Officer 48 -
Director TitleAgeSince
Chairman - 01/01/2024
Director/Board Member - 12/12/2024
Director/Board Member 55 14/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 106K
-0.55%+1.78%+40.65%+144.08% 1,286B
-1.00%+0.23%+41.68%+88.38% 688B
-0.25%+0.42%+25.86%+112.99% 521B
+1.14%+2.04%+42.51%+72.81% 386B
-1.41%-2.05%+56.91%+42.87% 364B
+1.27%+1.72%+28.34%+63.11% 302B
+0.37%-0.23%+3.25%+38.05% 287B
-0.54%-0.23%+35.83%+72.54% 252B
-0.60%-0.87%+35.26%+125.23% 208B
Average -1.90%+2.08%+34.48%+84.45% 477B
Weighted average by Cap. -0.37%+3.26%+36.66%+98.51%
Logo QuiaPEG Pharmaceuticals Holding AB
QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.
Employees
2
  1. Stock Market
  2. Stocks
  3. QUIA Stock